E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The patients should be < 20 years and reffered by an orthodontist with two contra lateral premolars in the upper jaw that has to be extracted. They should not have any diseases or medications that, according to the investigator, affects the security of the patient or the quality of the study. Furthermore, they should not have dental fear. |
Patienterna ska vara < 20 år och ha två premolarer bilateralt i maxillan som ska extraheras ortodontiskt enligt remiss från en ortodontist. De ska inte ha något sjukdomstillstånd eller medicinering som enligt prövarens bedömning påverkar patientens säkerhet eller studiens kvalité. De ska heller inte vara tandvårdsrädda. |
|
E.1.1.1 | Medical condition in easily understood language |
The patients should be < 20 years, healthy and have two contra lateral premolars in the upper jaw that has to be extracted orthodontically. |
Patienterna ska vara < 20 år, friska och ha två premolarer i maxillan som extraheras ortodontiskt. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of the study is to evaluate if the anesthetic effect and the patients' subjective experience is better when using cold than when using Lidocain gel 5%. |
Målet med studien är att utvärdera om bedövningseffekten och den subjektiva upplevelsen hos patient av kyla är bättre än vid användande av Lidokainsalva 5 %. |
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
Inte aktuellt |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• The patients should have two contra lateral premolars in the upper jaw that are going to be extracted orthodontically after a referral from an orthodontist • Age < 20år • Informed consent from patient and legal guardian when necessary (<18 years)
|
• Patienterna ska ha två premolarer bilateralt i maxillan som ska extraheras ortodontiskt enligt remiss från en ortodontist. • Ålder < 20år • Informerat samtycke från forskningsperson och vårdnadshavare i de fall det är nödvändigt (<18 år)
|
|
E.4 | Principal exclusion criteria |
• Disease or medication that according to the investigator affects the security of the patient or the quality of the study. • Expressed dental fear according to health declaration or according to the investigator. • Hypersensitivity to local anesthesia of amide type or to any of the other ingredients. |
• Sjukdomstillstånd eller medicinering som enligt prövarens bedömning påverkar patientens säkerhet eller studiens kvalité. • Uttalad tandvårdsrädsla enligt hälsodeklaration eller enligt tandläkarens bedömning • Överkänslighet mot lokalanestetika av amidtyp eller för något av de övriga innehållsämnena
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
According to the vas scale we expect ice to be at least 4mm lower on a 100mm vas scale. |
Utifrån VAS-skalan förväntas is ligga minst 4mm lägre på en 100mm Vas-skala |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline, 1min, 2,5min and 5min after application of local anaesthesia and after injection. |
Baseline, 1min, 2,5min och 5min efter applicering av lokalanestesi och efter injektion. |
|
E.5.2 | Secondary end point(s) |
70% of the patients will prefer ice over lidocain gel. |
70% av patienterna kommer att föredra is för lidokainsalva. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Questionnaire after the last visit |
Enkätsvar efter sista besöket |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Is är vår intervention. Lidokainsalva används som kontrollsubstans. |
Ice is used as test. Lidocaine gel is used as a comparator. |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last follow up phone call after LVLS |
Sista uppföljande telefonsamtal efter sista patientens sista besök. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |